75% ORR in G12C-experienced NSCLC sets BBO-8520 apart, but whether that signal survives an expanded dataset will determine if BBOT owns this niche

BridgeBio Oncology is a clinical-stage oncology company developing a targeted cancer drug for non-small cell lung cancer that has not yet been approved.

BBO-8520 achieved 75% ORR when combined with pembrolizumab in KRAS G12C inhibitor-experienced NSCLC patients, a notoriously resistant population where approved agents show limited benefit. The thesis holds if an expanded combination dataset confirms durable responses, validating a registrational path in a molecularly defined niche; Verastem's AVMAPKI/FAKZYNJA targets the same G12C-mutant NSCLC patient pool and represents a direct competitive threat. BBO-11818 and BBO-10203 add optionality in KRAS-mutant CRC and PDAC, but carry only safety-level evidence and remain unproven.